Skip to main content
SpringerLink
Log in

Neuroleptic Drugs and Their Management

  • Chapter
Psychosocial Interventions for People with Schizophrenia

Abstract

Neuroleptic drugs, also called antipsychotic drugs, are the mainstay treatment for schizophrenia. This type of drug is prescribed in acute episodes to control the distressing positive symptoms, hallucinations, delusions and thought interference and when given long-term for maintenance therapy its role is to prevent relapse. The importance of neuroleptic medication and its role in relapse prevention has been well established (Davis, 1975). However, a significant number, 30–40 per cent of people suffer relapses despite taking neuroleptics (Leff and Wing, 1971).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Addington, D., Addington, J. and Maticka-Tyndale, E. (1993) ‘Assessing Depression in Schizophrenia: The Calgery Depression Scale’, British Journal of Psychiatry, 163(suppl. 22), 39–44.

    Google Scholar 

  • Barnes, T.R.E. (1989) ‘A Rating Scale for Drug-Induced Akathisia’, British Journal of Psychiatry, 154, 672–6.

    Article  CAS  PubMed  Google Scholar 

  • Bazire, S. (2001/02) Psychotropic Drug Directory, Salisbury Quay Books.

    Google Scholar 

  • Bebbington, P.E. (1995) ‘The Content and Context of Compliance’, International Clinical Psychopharmacology, 9(suppl. 5), 41–50.

    Article  PubMed  Google Scholar 

  • Birchwood, M., Smith, J., Cochrane, R., Wetton, S. and Copestake, S. (1990) The social functioning scale: the development and validation of a scale of social adjustment for use in family intervention programmes with schizophrenic patients British Journal of Psychiatry, 157, 853–9.

    Article  CAS  PubMed  Google Scholar 

  • Brabbins, C., Butler, J. and Bentall, R. (1996) ‘Consent to Neuroleptic Medication for Schizophrenia: Clinical, Ethical and Legal Issues’, British Journal of Psychiatry, 168, 540–4.

    Article  CAS  PubMed  Google Scholar 

  • Braude, W., Barnes, T. and Gore, S. (1983) ‘Clinical characteristics of Akathisia: A systematic investigation of acute psychiatric inpatient admissions’, British Journal of Psychiatry, 143, 139–50.

    Article  CAS  PubMed  Google Scholar 

  • British National Formulary (BNF) (1999) British Medical Association and Royal Pharmaceutical Society of Great Britain, 38.

    Google Scholar 

  • Brown, K. and White, T. (1991) ‘The Psychological Consequences of Tardive Dyskinesia: The Effect of Drug-Induced Parkinsonism and the Topography of Dyskinesic Movements’, British Journal of Psychiatry, 159, 399–403.

    Article  CAS  PubMed  Google Scholar 

  • Chaplin, R. and Kent, A. (1998) ‘Informing patients about Tardive Dyskinesia’, British Journal of Psychiatry, 172, 78–81.

    Article  CAS  PubMed  Google Scholar 

  • Clozapine Study Group (1993) ‘The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK’, British Journal of Psychiatry, 163, 150–4.

    Article  Google Scholar 

  • Cohen, B., Baldessarini, R. and Pope, H. (1985) ‘Neuroleptic Malignant Syndrome’, New England Journal of Medicine, 313, 163–6.

    Article  Google Scholar 

  • Davis, J. (1975) ‘Overview: maintenance therapy in psychiatry — 1 schizophrenia’, American Journal of Psychiatry, 132, 1237–45.

    Article  CAS  PubMed  Google Scholar 

  • Day, J., Wood, G., Dewey, M. and Bentall, R. (1995) ‘A self rating scale for measuring neuroleptic side-effects; validation in a group of schizophrenic patients’, British Journal of Psychiatry, 166, 650–3.

    Article  CAS  PubMed  Google Scholar 

  • Department of Health and the Royal College of Nursing (1994) Good Practice in the Administration of Depot Neuroleptics, London, DoH/RCN.

    Google Scholar 

  • Department of Health (1994) Working in Partnership. A Collaborative Approach to Care, London, HMSO.

    Google Scholar 

  • Department of Health (1996) Building Bridges: A guide to arrangements for interagency working for the care and protection of severely mentally ill people, London, HMSO.

    Google Scholar 

  • Department of Health (1999) Modern Standards and Service Models — National Service Frameworks, London, The Stationery Office.

    Google Scholar 

  • Grey, R., Gournay, K. and Taylor, D. (1997) ‘New Drug Treatment for Schizophrenia: Implications for Nursing Practice’, Mental Health Practice, 1, 20–3.

    Article  Google Scholar 

  • Hubbard, J., Midha, K. and Hawes, E., et al. (1993) ‘Metabolism of phenothiazine and butyrophenone antipsychotic drugs: A review of some recent research findings and clinical implications’, British Journal of Psychiatry, 163(Suppl. 22), 19–24.

    Google Scholar 

  • Kane, J.M. (1985) ‘Compliance Issues in Outpatient Treatment’, Journal of Clinical Psychopharmacology, 5, 22–7.

    Article  Google Scholar 

  • Kane, J.M. (1992) ‘Clinical efficacy of clozapine in treatment of treatment refractory schizophrenia: an overview’, British Journal of Psychiatry, 160(Suppl.), 41–5.

    Google Scholar 

  • Kerwin, R.W. (1994) ‘The new atypical antipsychotics: A lack of extra-pyramidal side-effects and new routes in schizophrenia research’, British Journal of Psychiatry, 164, 141–8.

    Article  CAS  PubMed  Google Scholar 

  • Kissling, W. (1992) ‘Ideal and Reality of Neuroleptic Relapse Prevention’, British Journal of Psychiatry, 161(Suppl. 18), 133–9.

    Google Scholar 

  • Krawiecka, M., Goldberg, D. and Vaughan, M. (1977) ‘A standardised psychiatric assessment scale for rating chronic psychotic patients’, Acta Psychiatrica Scandinavica, 55, 299–308.

    Article  CAS  PubMed  Google Scholar 

  • Leff, J.P. and Wing, J.K. (1971) ‘Trial of maintenance therapy in schizophrenia’, British Medical Journal, 3, 599–604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lewander, T. (1994) ‘Neuroleptics and the Neuroleptic Induced Deficit Syndrome’, Acta Psychiatrica Scandinavica, 380(Suppl.), 3–13.

    Google Scholar 

  • Liberman, R., Marder, S., Marshall, B.D., Mintz, J. and Kuehnel, T. (1998) ‘Biobehavioural Therapy: Pharmacotherapy and Behaviour Therapy in Schizophrenia’, in T. Wykes, N. Tarrier and S. Lewis (eds), Outcome and Innovation in Psychological Treatment of Schizophrenia, Chichester, Wiley.

    Google Scholar 

  • Marder, S. (1992) ‘Pharmacological Treatment of Schizophrenia’ in D. Kavanagh (ed.), Schizophrenia: an Overview and Practical Handbook, London, Chapman & Hall.

    Google Scholar 

  • Mitchell, J. and Popkin, M. (1982) ‘Antipsychotic drug therapy and sexual dysfunction in men’, American Journal of Psychiatry, 139, 633–7.

    Article  CAS  PubMed  Google Scholar 

  • Morrison, D. (1996) ‘Management of Treatment Refractory Schizophrenia’, British Journal of Schizophrenia, 169(suppl.), 15–20.

    Google Scholar 

  • National Institute of Mental Health (1975) ‘Abnormal Involuntary Movement Scale’, Early Clinical Drug Evaluation Unit Intercom, 4, 3–6.

    Google Scholar 

  • Pratt, P. (1998) ‘The Administration and Monitoring of Neuroleptic Medication’, in Brooker and Repper (eds), Serious Mental Health Problems in the Community. Policy, Practice and Research, Baillière Tindall, London.

    Google Scholar 

  • Schooler, N. (1993) ‘Reducing dosage in maintenance treatment of schizophrenia: review and prognosis’, British Journal of Psychiatry, 163(Suppl.), 58–65.

    Google Scholar 

  • Silverstone, T. and Turner, P. (1991) Drug Treatment in Psychiatry, London, Routledge.

    Google Scholar 

  • Simpson, G. and Angus, J. (1970) ‘A rating scale for extrapyramidal side effects’, Acta Psychiatrica Scandinavica, 44, 11–19.

    Article  Google Scholar 

  • Siris, S. (1993) ‘Adjunctive medication in the maintenance treatments for schizophrenia and its conceptual implications’, British Journal of Psychiatry, 163(Suppl.), 66–78.

    Google Scholar 

  • Thomas, C. and Lewis, S. (1998) ‘Which Atypical Antipsychotic?’, British Journal of Psychiatry, 172, 106–9.

    Article  CAS  PubMed  Google Scholar 

  • UKCC (1998) Guidelines for Mental Health and Learning Disabilities Nursing, London, UKCC.

    Google Scholar 

  • Warner, R. (1994) Recovery from Schizophrenia, London, Routledge.

    Google Scholar 

  • Zigmond, A. and Snaith, R. (1983) ‘Hospital Anxiety and Depression Scale’ Acta Psychiatrica Scandinavica, 67, 361–70.

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. Neil Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Nursing, Midwifery and Health Visiting, University of Manchester, UK

    Neil Harris (Practice Development Nurse for the Community with Manchester Mental Health and Social Care Trust and Honorary Lecturer) & Steve Williams (Senior Cognitive Behaviour Nurse Therapist, Mental Health Services of Salford, and Honorary Lecturer) (Practice Development Nurse for the Community with Manchester Mental Health and Social Care Trust and Honorary Lecturer) &  (Senior Cognitive Behaviour Nurse Therapist, Mental Health Services of Salford, and Honorary Lecturer)

  2. Merseycare Mental Health Care NHS Trust, UK

    Tim Bradshaw (Lecturer, COPE Initiative, School of Nursing, Midwifery and Health) (Lecturer, COPE Initiative, School of Nursing, Midwifery and Health)

Copyright information

© 2002 Neil Harris, Steve Williams, Tim Bradshaw

About this chapter

Cite this chapter

Harris, N. (2002). Neuroleptic Drugs and Their Management. In: Harris, N., Williams, S., Bradshaw, T. (eds) Psychosocial Interventions for People with Schizophrenia. Palgrave, London. https://doi.org/10.1007/978-1-4039-3759-9_6

Download citation

Publish with us

Policies and ethics

Search

Navigation